Afamelanotide

What it's for

Afamelanotide is a regulated melanocortin peptide medicine. In the U.S. it is known as Scenesse for a rare disease that makes sunlight painful. It helps adults with erythropoietic protoporphyria (EPP) increase pain-free time in light, under specialty care.

What it does for the body

It helps adults with erythropoietic protoporphyria (EPP) increase pain-free time in light, under specialty care. It is not approved as a general tanning or beauty product. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.

What it targets

It turns on melanocortin receptors (landing spots on cells) that raise protective pigment. Picture lock-and-key on pigment pathways — used as a monitored medicine implant/program, not a spa tan. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.

Research context

Bottom line for readers: Afamelanotide has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.

Studied for (literature interest)

• Skin research interest (educational tag)

Cautions (educational)

• Educational only — not medical advice.
• DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.

Citations / starters

• FDA search: Afamelanotide — FDA.gov search
• ClinicalTrials.gov search: Afamelanotide — U.S. clinical trials registry
• Drugs@FDA search: Afamelanotide — FDA drug database (if approved)
• PubMed search: Afamelanotide — NCBI PubMed
• PubMed Central search: Afamelanotide — NCBI PMC

Reference

No ref on file.